Brief: Surface Oncology Says Therapy SRF388 Demonstrates Monotherapy Activity
04/06/2021 12:25
June 4 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY INC - SRF388, A FIRST-IN-CLASS IL-27
ANTIBODY,
DEMONSTRATES MONOTHERAPY ACTIVITY IN DATA PRESENTED AT ASCO
ANNUAL MEETING
* SURFACE ONCOLOGY INC - PRELIMINARY DATA FOR SRF617 SHOW
GOOD
TOLERABILITY AND PROMISE IN COMBINATION APPROACHES
Source text for Eikon: ID:nGNX3DSlqR
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing